Stay updated on M7824 and Topotecan in Relapsed SCLC Clinical Trial
Sign up to get notified when there's something new on the M7824 and Topotecan in Relapsed SCLC Clinical Trial page.

Latest updates to the M7824 and Topotecan in Relapsed SCLC Clinical Trial page
- ChecktodayChange DetectedRevision: v3.3.4 was applied, replacing the previous v3.3.3. The update appears to be a metadata/version bump with no visible changes to the study details or eligibility information.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedAdded a Locations section and Maryland as a location. Updated from revision v3.3.2 to v3.3.3, and removed the Maryland Locations entry and the HHS Vulnerability Disclosure.SummaryDifference0.1%

- Check50 days agoChange DetectedRevision changed from v3.3.1 to v3.3.2, which appears to be an administrative metadata update and does not affect study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision history updated from v3.2.0 to v3.3.1; no substantive changes to the study details observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page removed the funding-status notice about potential delays due to government funding, removing a site-wide operational alert. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check79 days agoChange DetectedNo additions or deletions of significant content were detected, and the page content remains unchanged.SummaryDifference0.3%

Stay in the know with updates to M7824 and Topotecan in Relapsed SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the M7824 and Topotecan in Relapsed SCLC Clinical Trial page.